Please login to the form below

Not currently logged in
Email:
Password:

asthma drug

This page shows the latest asthma drug news and features for those working in and with pharma, biotech and healthcare.

Sanofi’s new CEO cuts first deal, adding Synthorx for $2.5bn

Sanofi’s new CEO cuts first deal, adding Synthorx for $2.5bn

cancer as well as autoimmune indications, headed by a drug for solid tumours that is in a phase 1 trial. ... drug  Dupixent (dupilumab) – but also failures such as dengue vaccine Dengvaxia and underperforming cholesterol drug Praluent (alirocumab).

Latest news

  • Novartis strengthens case for its combination asthma drug Novartis strengthens case for its combination asthma drug

    Demonstrated significant benefits in uncontrolled asthma patients. Novartis has unveiled positive phase 3 data for its dual combination asthma drug QMF149, strengthening its case for approval with regulators. . ... QMF149 also met the secondary endpoint

  • Sanofi said to be looking at options for $30bn consumer health unit Sanofi said to be looking at options for $30bn consumer health unit

    Sanofi has had a difficult few years following the loss of patent protection for its former diabetes cash cow Lantus (insulin glargine), with some pipeline successes – notably atopic dermatitis and asthma ... There have been some failures as well

  • The end of pharma The end of pharma

    Well, twice in recent weeks I’ve worked with companies in chronic diseases – diabetes and asthma. ... Both began their thinking worrying about how to evolve their product – in the first case a continuous blood sugar monitor, in the second an asthma

  • GSK boosts outlook thanks to strong respiratory and vaccine sales GSK boosts outlook thanks to strong respiratory and vaccine sales

    Key Q3 drivers include Shingrix vaccine and asthma drug Nucala. GlaxoSmithKline has raised its profit forecast for the second consecutive quarter thanks to the strong sales of its shingles vaccine Shingrix ... The drug is on track to be filed for

  • Sanofi's Dupixent gains asthma approval in Europe Sanofi's Dupixent gains asthma approval in Europe

    Drug on track to meet blockbuster forecasts. Sanofi and Regeneron’s Dupixent will now enter the asthma market in Europe, the new expansion confirming its blockbuster profile. ... Already approved in atopic dermatitis, the drug can now be used an add-on

More from news
Approximately 2 fully matching, plus 115 partially matching documents found.

Latest Intelligence

  • The long and winding road to asthma breakthroughs The long and winding road to asthma breakthroughs

    This was the turning point for the development programme.”. The late nights interrogating the science and unpicking data sets prompted the switch from a drug for the broad asthma community to ... a therapy targeted at a subtype representing around 10%

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    Researchers are now trying to identify biomarker-based subgroups and drug combinations to try to improve therapeutic outcomes for patients. ... up innate immune responses, and Cancer Research UK is repurposing an AZ chemokine CCR4 receptor drug (AZD2098)

  • US health reforms US health reforms

    In fact, it’s safe to say most C-suite drug executives would hardly shed a tear upon news of Obamacare’s swift demise. ... To cite just one example, patients with financial need get an 85% discount on the popular asthma drug Advair, and that’s by

  • Building BRICs: pharma's key emerging markets are becoming giants Building BRICs: pharma's key emerging markets are becoming giants

    In April 2013, Novartis was denied patent protection for its cancer drug, Glivec, by the Indian Supreme Court. ... This follows similar patent defeats in India for Pegasys, Roche's hepatitis drug, Merck's asthma treatment, Singulair, Gilead's Viread (HIV)

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Enterprise Therapeutics appoints CEO Enterprise Therapeutics appoints CEO

    He joins the drug discovery firm from Xention Discovery, where he had served as chief scientific officer since co-founding the company in 2002. ... Discovery. Dr Peter Finan, chairman of Enterprise Therapeutics, said: “John's experience in ion channels,

  • Former RBS head takes the reins as GSK chair Former RBS head takes the reins as GSK chair

    the past year, and to develop new products in order to offset the decline of its best-selling asthma drug, Advair, as part of his new remit.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

Pharma index map
The 2019 CPhI Pharma Index Report
Examining this year’s industry performance...
Five key trends in precision and personalised healthcare
Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...
OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications
Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...

Infographics